Respiratory syncytial virus (RSV) usually causes mild, cold-like symptoms in most people, but it is the leading cause of infant hospitalization in the U.S.

In August and September 2023, CDC and the Advisory Committee on Immunization Practices recommended two RSV prevention products to prevent RSV-associated lower respiratory tract …

Recommendations and Clinical Guidance for Use of RSV Vaccines in Older Adults and Pregnant People and Use of Nirsevimab in Infants and Young Children

4 days ago · The next step is a vote from the CDC's vaccine advisory committee. The U.S. Food and Drug Administration expanded its approval of Moderna's respiratory syncytial virus (RSV) …

Jun 26, 2024 · Since the CDC first recommended the vaccine for use in ages 60 and older in June 2023, the Food and Drug Administration (FDA) at the end of May approved a third RSV …

receive RSV vaccine during preg-nancy, and some children ages 8-19 months who are at increased risk for severe RSV October through March* Babies RSV vaccine (Pfizer’s …

Aug 30, 2024 · CDC recommends a single dose of any FDA-licensed RSV vaccine for all adults ages 75 and older and adults ages 60–74 at increased risk of severe RSV. Adults who have …

Jun 10, 2025 · Two to three percent of infants under 6 months are hospitalized with RSV in the US every year, according to the CDC. Among children younger than 5, about 58,000 to 80,000 …

Sep 18, 2024 · Respiratory syncytial virus (RSV) is a leading cause of illness in infants . Previous epidemiologic studies of RSV infection during infancy have focused on symptomatic illness, …

Sep 25, 2023 · At this time, the RSV preventive antibody is not part of the Vaccine Injury Compensation Program (VICP), therefore use of the IIS is not required by federal law in the …